Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Gross Profit: 2021-2024

Historic Gross Profit for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Dec 2024 value amounting to $170.1 million.

  • Tarsus Pharmaceuticals' Gross Profit rose 145.98% to $110.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.4 million, marking a year-over-year increase of 183.32%. This contributed to the annual value of $170.1 million for FY2024, which is 973.09% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Gross Profit stood at $170.1 million for FY2024, which was up 973.09% from $15.9 million recorded in FY2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Gross Profit peaked at $170.1 million during FY2024, and registered a low of $15.9 million during FY2023.
  • Moreover, its 3-year median value for Gross Profit was $24.9 million (2022), whereas its average is $70.3 million.
  • In the last 5 years, Tarsus Pharmaceuticals' Gross Profit tumbled by 54.76% in 2022 and then spiked by 973.09% in 2024.
  • Yearly analysis of 4 years shows Tarsus Pharmaceuticals' Gross Profit stood at $55.0 million in 2021, then tumbled by 54.76% to $24.9 million in 2022, then slumped by 36.23% to $15.9 million in 2023, then soared by 973.09% to $170.1 million in 2024.